Should You Sell Agile Therapeutics Inc (AGRX) in Drug Manufacturers

The 44 rating InvestorsObserver gives to Agile Therapeutics Inc (AGRX) stock puts it near the top of the Drug Manufacturers - Specialty & Generic industry. In addition to scoring higher than 71 percent of stocks in the Drug Manufacturers - Specialty & Generic industry, AGRX’s 44 overall rating means the stock scores better than 44 percent of all stocks.

AGRX has an Overall Score of 44. Find out what this means to you and get the rest of the rankings on AGRX!

See Full AGRX Report

What do These Ratings Mean?

Analyzing stocks can be hard. There are tons of numbers and ratios, and it can be hard to remember what they all mean and what counts as “good” for a given value. InvestorsObserver ranks stocks on eight different metrics. We percentile rank most of our scores to make it easy for investors to understand. A score of 44 means the stock is more attractive than 44 percent of stocks. These rankings allows you to easily compare stocks and view what the strengths and weaknesses are of a given company. This lets you find the stocks with the best short and long term growth prospects in a matter of seconds. The combined score incorporates technical and fundamental analysis in order to give a comprehensive overview of a stocks performance. Investors who then want to focus on analysts rankings or valuations are able to see the separate scores for each section.

What's Happening With Agile Therapeutics Inc Stock Today?

Agile Therapeutics Inc (AGRX) stock is down -14.23% while the S&P 500 is up 0.17% as of 1:40 PM on Monday, May 16. AGRX is lower by -$0.23 from the previous closing price of $1.63 on volume of 366,360 shares. Over the past year the S&P 500 has fallen -3.18% while AGRX is lower by -97.76%. AGRX lost -$30.86 per share the over the last 12 months. Click Here to get the full Stock Report for Agile Therapeutics Inc stock.